Generic Frova Launched


Mylan has launched frovatriptan succinate tablets, 2.5 mg, which are the generic equivalent to Endo's Frova tablets.

Mylan has launched frovatriptan succinate tablets, 2.5 mg, which are the generic equivalent to Endo’s Frova tablets.

The FDA recently granted approval for Mylan’s abbreviated new drug application for the acute migraine headache treatment for adults.

The safety and efficiency of Frova was examined in 5 double-blind, placebo-controlled, outpatient trials. The trials showed that the drug could reduce the pain associated with moderate to severe headaches.

The most common adverese effects were nausea, vomiting, phonophobia, and photophobia.

Frova is not recommended for patients with ischemic heart disease or uncontrolled hypertension.

US sales for this drug reached approximately $88 million for the 12 months ending in March 31, 2016, according to IMS Health.

To date, Mylan has 260 abbreviated new drug applications pending FDA approval.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.